Yixin Zhai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yixin Zhai has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Fei Teng
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
9 shared publications - Hongyu Wang
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
9 shared publications - Jianming Ying
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
9 shared publications - Junling Li
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
9 shared publications - Puyuan Xing
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
9 shared publications - Shouzheng Wang
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
9 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
The TMB distribution of all primary and metastases samples. The total TMB (defined as the number of nonsynonymous mutations) in each group.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
The TMB distribution of all primary and metastases samples. The total TMB (defined as the number of nonsynonymous mutations) in each group.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
Brain metastases (BM) is one of the main reasons for lung cancer-related deaths but lack prediction methods. Many patients with BMs do not benefit from immunotherapy. A comprehensive genomic analysis of matched primary tumors (PT) and their BM lesions may provide new insight into the evolutionary and immune characteristics. To describe evolutionary features and immune characteristic differences, we analyzed whole-exome sequencing data for 28 paired PT and BM samples from 14 patients with non-small cell lung cancer. In addition, we used another 26 matched PT and BM samples as a validation cohort. We found that total mutational signatures were relatively consistent between paired primary and brain metastatic tumors. Nevertheless, the shared mutations of the two lesions were fewer than the mutations present in each of the lesions alone. In the process of BM, driver genes undergo evolutionary branches. Typical driver genes, including EGFR and TP53, appear relatively conserved throughout evolution; however, specific signals are enriched in BM lesions. We found several main characteristics of lung cancer BMs that were different from primary lung cancer, such as genomic instability, novel driver genes, tumor mutation burden, and BM lesion private neoantigens. In addition, the estimated timing of dissemination showed that BMs might occur early in lung cancer.Implications:Mechanistic insight from this study provides new insight into the biology of the metastatic brain process and a new beneficial approach for preventing and treating lung cancer BMs.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
Brain metastases (BM) is one of the main reasons for lung cancer-related deaths but lack prediction methods. Many patients with BMs do not benefit from immunotherapy. A comprehensive genomic analysis of matched primary tumors (PT) and their BM lesions may provide new insight into the evolutionary and immune characteristics. To describe evolutionary features and immune characteristic differences, we analyzed whole-exome sequencing data for 28 paired PT and BM samples from 14 patients with non-small cell lung cancer. In addition, we used another 26 matched PT and BM samples as a validation cohort. We found that total mutational signatures were relatively consistent between paired primary and brain metastatic tumors. Nevertheless, the shared mutations of the two lesions were fewer than the mutations present in each of the lesions alone. In the process of BM, driver genes undergo evolutionary branches. Typical driver genes, including EGFR and TP53, appear relatively conserved throughout evolution; however, specific signals are enriched in BM lesions. We found several main characteristics of lung cancer BMs that were different from primary lung cancer, such as genomic instability, novel driver genes, tumor mutation burden, and BM lesion private neoantigens. In addition, the estimated timing of dissemination showed that BMs might occur early in lung cancer.Implications:Mechanistic insight from this study provides new insight into the biology of the metastatic brain process and a new beneficial approach for preventing and treating lung cancer BMs.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
The basic clinical information of all patients.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
The basic clinical information of all patients.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
Supplementary Figure 1. The TMB distribution of all primary and metastases samples. The total TMB (defined as the number of nonsynonymous mutations) in each group.Supplementary Table 1. The basic clinical information of all patients.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
Supplementary Figure 1. The TMB distribution of all primary and metastases samples. The total TMB (defined as the number of nonsynonymous mutations) in each group.Supplementary Table 1. The basic clinical information of all patients.
- Open Access
- 19 December 2022
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 21 (4) , 374-385
Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
Brain metastases (BM) is one of the main reasons for lung cancer-related deaths but lack prediction methods. Many patients with BMs do not benefit from immunotherapy. A comprehensive genomic analysis of matched primary tumors (PT) and their BM lesions may provide new insight into the evolutionary and immune characteristics. To describe evolutionary features and immune characteristic differences, we analyzed whole-exome sequencing data for 28 paired PT and BM samples from 14 patients with non-small cell lung cancer. In addition, we used another 26 matched PT and BM samples as a validation cohort. We found that total mutational signatures were relatively consistent between paired primary and brain metastatic tumors. Nevertheless, the shared mutations of the two lesions were fewer than the mutations present in each of the lesions alone. In the process of BM, driver genes undergo evolutionary branches. Typical driver genes, including EGFR and TP53, appear relatively conserved throughout evolution; however, specific signals are enriched in BM lesions. We found several main characteristics of lung cancer BMs that were different from primary lung cancer, such as genomic instability, novel driver genes, tumor mutation burden, and BM lesion private neoantigens. In addition, the estimated timing of dissemination showed that BMs might occur early in lung cancer. Implications: Mechanistic insight from this study provides new insight into the biology of the metastatic brain process and a new beneficial approach for preventing and treating lung cancer BMs.
- 19 December 2022
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 21 (4) , 374-385
Open AccessEvolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
Brain metastases (BM) is one of the main reasons for lung cancer-related deaths but lack prediction methods. Many patients with BMs do not benefit from immunotherapy. A comprehensive genomic analysis of matched primary tumors (PT) and their BM lesions may provide new insight into the evolutionary and immune characteristics. To describe evolutionary features and immune characteristic differences, we analyzed whole-exome sequencing data for 28 paired PT and BM samples from 14 patients with non-small cell lung cancer. In addition, we used another 26 matched PT and BM samples as a validation cohort. We found that total mutational signatures were relatively consistent between paired primary and brain metastatic tumors. Nevertheless, the shared mutations of the two lesions were fewer than the mutations present in each of the lesions alone. In the process of BM, driver genes undergo evolutionary branches. Typical driver genes, including EGFR and TP53, appear relatively conserved throughout evolution; however, specific signals are enriched in BM lesions. We found several main characteristics of lung cancer BMs that were different from primary lung cancer, such as genomic instability, novel driver genes, tumor mutation burden, and BM lesion private neoantigens. In addition, the estimated timing of dissemination showed that BMs might occur early in lung cancer. Implications: Mechanistic insight from this study provides new insight into the biology of the metastatic brain process and a new beneficial approach for preventing and treating lung cancer BMs.